Featured Research

from universities, journals, and other organizations

Secreted Protein Sends Signal That Fat Is On The Way

Date:
December 11, 2008
Source:
Cell Press
Summary:
After you eat a burger and fries or other fat-filled meal, a protein produced by the liver may send a signal that fat is on the way, suggests a new report.

After you eat a burger and fries or other fat-filled meal, a protein produced by the liver may send a signal that fat is on the way, suggests a report in the December issue of the journal Cell Metabolism, a Cell Press publication.

Researchers have found in mice that the liver produces a protein called adropin, which rises in response to high-fat foods and falls after fasting. The protein seems to play a role in governing the activity of other metabolic genes, particularly those involved in the production of lipids from carbohydrates. Studies of the protein in obese animals suggest that it also plays a role in insulin response and in preventing the buildup of fat in the liver (a condition known as nonalcoholic fatty liver disease), the researchers said.

"What is remarkable is that it appears that this factor is specifically regulated by the fat content of the diet," making it one of the first such factors ever discovered, said Andrew Butler of Pennington Biomedical Research Center, part of the Louisiana State University System. (The findings follow another report in the November 26th issue of the journal Cell of a phospholipid produced by the gut that rises after a fatty meal, signaling the brain to eat less.)

The new results suggest that treatments designed to deliver adropin or otherwise boost its levels may hold promise in the war against obesity and associated metabolic disorders, including fatty liver disease and type 2 diabetes.

Indeed, Butler's team found that animals that become obese after eating a high-fat diet for a period of 3 months or due to a genetic mutation don't produce adropin normally. However, obese animals that are manipulated to produce excess adropin or that are given the protein show less fat in their livers and become more responsive to insulin. The mice also ultimately eat less and lose weight, but the other metabolic improvements do not depend on the animals' shrinking waistlines, Butler said.

"The good news is that when you provide a synthetic version of the peptide, it reverses some of the consequences of obesity," he said.

Butler noted, however, that there is still plenty left to learn. For instance, they would like to know whether mice that lack adropin become obese and show evidence of the metabolic syndrome, a cluster of diseases associated with obesity and insulin resistance. The protein is also produced in the brain, suggesting it may also affect behavior and metabolism in as-yet-undiscovered ways. The clinical promise of adropin will depend on whether the relationships between the protein, diet, and metabolism seen in mice will hold in human patients.

The researchers aren't yet certain exactly how adropin works its magic. Its benefits could involve effects within the liver and/or hormonal actions on other body tissues, they said. The answers to those questions will require further investigation.

"In summary," the researchers wrote, "adropin is a newly discovered secreted peptide that is involved in energy homeostasis and lipid metabolism … Adropin may form the basis for the development of new therapeutic targets for treating metabolic disorders associated with obesity."

The researchers include K. Ganesh Kumar, Louisiana State University System, Baton Rouge, LA; James L. Trevaskis, Louisiana State University System, Baton Rouge, LA; Daniel D. Lam, University of Cambridge, Cambridge, UK; Gregory M. Sutton, Louisiana State University System, Baton Rouge, LA; Robert A. Koza, Louisiana State University System, Baton Rouge, LA; Vladimir N. Chouljenko, Louisiana State University, Baton Rouge, LA; Konstantin G. Kousoulas, Louisiana State University, Baton Rouge, LA; Pamela M. Rogers, Louisiana State University System, Baton Rouge, LA; Robert A. Kesterson, University of Alabama at Birmingham, Birmingham, AL; Marie Thearle, Louisiana State University System, Baton Rouge, LA; Anthony W. Ferrante Jr., Louisiana State University System, Baton Rouge, LA; Randall L. Mynatt, Louisiana State University System, Baton Rouge, LA; Thomas P. Burris, Louisiana State University System, Baton Rouge, LA; Jesse Z. Dong, Biomeasure Incorporated, IPSEN, Milford, MA; Heather A. Halem, Biomeasure Incorporated, IPSEN, Milford, MA; Michael D. Culler, Biomeasure Incorporated, IPSEN, Milford, MA; Lora K. Heisler, University of Cambridge, Cambridge, UK; Jacqueline M. Stephens, Louisiana State University, Baton Rouge, LA; and Andrew A. Butler, Louisiana State University System, Baton Rouge, LA, Louisiana State University System, Baton Rouge, LA.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Secreted Protein Sends Signal That Fat Is On The Way." ScienceDaily. ScienceDaily, 11 December 2008. <www.sciencedaily.com/releases/2008/12/081202133218.htm>.
Cell Press. (2008, December 11). Secreted Protein Sends Signal That Fat Is On The Way. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/12/081202133218.htm
Cell Press. "Secreted Protein Sends Signal That Fat Is On The Way." ScienceDaily. www.sciencedaily.com/releases/2008/12/081202133218.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins